Untitled - D Ank Unlimited

BALT 101 basolateral
A
B
C
H & E
T-cells
B-cells
PA
L
BALT.
300 µm
BALT
See bronchial-associated lymphoid tissue and MALT.
band test
Antigen–antibody deposits at the dermal–epidermal
junctions in patients with lupus erythematosus. They may
consist of IgG, IgM, IgA, and C3. Deposits are not found
in uninvolved areas of the dermal–epidermal junctions in
discoid lupus erythematosus (DLE) but are present in both
involved and uninvolved areas of the junctions in systemic
lupus erythematosus (SLE). Immune complexes at the
dermal–epidermal junction appear in 90 to 95% of SLE
patients. Ninety percent reveal them in skin exposed to sunlight,
and 50% have deposits in skin not exposed to the sun.
Also called lupus band test. Immunofluorescence bands
also occur in some cases of anaphylactoid purpura, atopic
dermatitis, contact dermatitis, autoimmune thyroiditis,
bullous pemphigoid, cold agglutinin syndrome, dermatomyositis,
hypocomplementemic vasculitis, polymorphous light
eruption, rheumatoid arthritis, scleroderma, and a number
of other conditions.
bare lymphocyte syndrome (BLS)
Rare autosomal-recessive disorders in which individuals
manifest little or no expression of human leukocyte antigen
(HLA) major histocompatibility proteins. BLS has been
classified into three types that are of varying severity with
respect to phenotypic HLA expression and loss of immune
C
GC
function. BLS type I patients have little or no expression of
HLA class I molecules on peripheral blood cells. They may
have a broad range of immunodeficiency, with some individuals
even revealing normal immunity. Type II BLS is
characterized by a reduction or complete loss of HLA class
II protein expression on all cells. This disorder is usually
expressed as a severe combined immunodeficiency. In BLS
type III, there is decreased expression of both HLA class I
and class II antigen expression. These patients have severe
immunodeficiency. HLA class I deficiency is sometimes
referred to as type I BLS. It is believed that low expression
of class I molecules may be sufficient for immune responses
against pathogens, whereas complete deficiency would be
lethal. Contrary to type II and III BLS, characterized by
early onset of severe combined immunodeficiency (SCID),
class I antigen deficiencies are not accompanied by specific
pathologic features during the first years of life, although
chronic lung disease develops in late childhood. In contrast
to type II or III BLS, pathology of the gastrointestinal tract
(diarrhea) is not observed. The lack of MHC molecule
expression on the cells is due to a deficiency of the RFX or
CIITA components of the SXY-CITTA regulatory system.
Thus, the syndrome may be attributable to various different
regulatory gene defects leading to severe immune
deficiency.
barrier filter
A device in the eyepiece of an ultraviolet light source
microscope employed for fluorescent antibody techniques
to protect the viewer’s eyes from injury by ultraviolet
radiation. It also facilitates observation of the fluorescence
by blocking light of the wavelength that produces fluorochrome
excitation.
bas
Mutation in an mRNA splicing acceptor site in the rabbit
that leads to diminished expression of the principal type of
immunoglobulin κ light chain (MO-κ-1). Rabbits with the
bas mutation have λ light chains, although a few have the
κ-2 isotype of light chains.
basement membrane
A structure comprised of collagen, laminin, heparan sulfate,
and glycosaminoglycan beneath an overlying epithelial
or endothelial cell layer.
basement membrane antibody
Antibody specific for the basement membranes of various
tissues such as lung basement membranes, glomerular
basement membranes, etc. This antibody is usually
observed by immunofluorescence and less often by immunoperoxidase
technology.
basiliximab (injection)
An immunosuppressive agent that acts as an IL-2 receptor
antagonist by binding with high affinity to the α chain
of the high affinity IL-2 receptor complex and inhibiting
IL-2 binding. It is specific for IL-2Rα, which is expressed
on activated T cell surfaces. High affinity binding of
basiliximab to IL-2Rα inhibits IL-2 mediated activation
of lymphocytes, which is critical in cellular immune
responsiveness in allograft rejection. It blocks responses
of the immune system to antigenic challenges when in the
circulation.
basolateral
The epithelial cell surface that faces the tissue instead of
the lumen.
B